Description

Cultrex®Human Vitronectin,Pathclear®ispurifiedfromhumanplasmaandisPathclear®certifiedtobefreeofcommonpathogens.Vitronectinisanextracellular,soluble,disulfide-linkeddimer,composedofa75kDaanda65kDapeptidechainwithatotalmolecularweightof140kDa.VitronectinisamajorplasmaglycoproteinthatpromotescellularadhesionandspreADIng.Italsoinhibitsthemembranedamagingeffectoftheterminalcytolyticcomplementpathwayandbindstoseveralserpinserineproteaseinhibitors.Vitronectin,alongwithcollagenIV,fibronectin,andlaminincansupportrobust,longtermproliferationofundifferentiatedhumanembryonicstemcells.Vitronectincanbeusedforcoatingtissueculturesurfacestopromotecelladhesion,proliferationanddifferentiation,orasanadditiveforserum-freemedia.Vitronectinispurifiedfromhumanplasmaandis0.2μmsterilefiltered.

Cultrex®HumanVitronectin,Pathclear®isapurifiedplasmaextracellularmatrix proteinthathasbeendeveloped,producedandqualifiedspecifically forcellculturestudieswherethepresenceofpathogensmaycauseconcern.

Qualitycontrolspecifications:

• PathClear®–testednegativeforeighthumanpathogenicvirusesincludingHepatitisA,BandC,HIV1and2,Hantaan,Seoul,andSinNombrebyPCR.
• Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPsterilitytestingguidelines.
• Endotoxinconcentration≤20EU/mlbyLimulusAmoebocyteLysate(LAL)assay.
• Proteinconcentrationof1mg/ml.
• NomycoplasmacontaminationdetectedbyPCR.
• Providedin10mMSodiumPhosphate,pH7.7,8MUrea,5mMEDTA,500mMNaCl.
• Purity ≥90%(SDS-PAGE).
• BIOLOGicalactivitydeterminedforeachlot:
  • CellAttachment:TestedfortheABIlitytopromotecellattachmentandspreadingofHT1080humanfibrosarcomacells.

SafetyStatement:

AlthoughCultrex®HumanVitronectin,PathClear®hasbeentestedforthevirusesaboveitcontainshumansourcematerialandthereforeshouldbetreatedaspotentiallyinfectiousandhandledattheBiologicalSafetyLevel2tominimizeexposure.